Morepen Laboratories Reports Record Q2 FY27 Driven by Robust CDMO Scale-Up
Morepen Laboratories Ltd 路 Press Release 路 27 Oct 2026, 7:09 pm
Morepen Laboratories Reports Record Q2 FY27 Driven by Robust CDMO Scale-Up Morepen Laboratories reported record Q2 FY27 revenue of Rs. 755 Cr, up 81% YoY, with EBITDA surging 273% YoY to Rs. 132 Cr as margins expanded 897 bps to 17.45%. PAT rose 117% YoY to Rs. 89 Cr. Growth was propelled by commercial CDMO scale-up, generating Rs. 253 Cr in Q2 (52% of API+CDMO revenue). Exports jumped 131% to Rs. 397 Cr, and Medical Devices grew 65% to Rs. 208 Cr. API+CDMO capacity reached 614 KL, targeting 800 KL by Q2 FY28.
Original exchange filing (PDF)
More announcements from Morepen Laboratories Ltd
- Update on Credit Rating 路 14 Nov 2026
- Please find attached the Press Release 路 09 Nov 2026
- Change in Senior Management Personnel on account of resignation 路 31 Oct 2026
- Change in Designation of Senior Management Personnel of the Company 路 28 Oct 2026
- Please find attached the monitoring agency report for the quarter ended September 30, 2026 路 27 Oct 2026
- Please find attached the Investor Presentation for Q2 & H1 FY 27 Financial Results 路 27 Oct 2026
- Please find attached the Q2 & H1 FY 27 Financial Results 路 27 Oct 2026
- Please find attached the Q2 & H1 FY27 Financial Results along with Limited Review Report 路 27 Oct 2026
